TY - CHAP M1 - Book, Section TI - Indications for Bone-Modifying Agents in Hematology-Oncology A1 - Shalabi, Reem Abozena A1 - Frame, James N. A2 - Boyiadzis, Michael M. A2 - Frame, James N. A2 - Kohler, David R. A2 - Fojo, Tito PY - 2016 T2 - Hematology-Oncology Therapy, 2e AB - Primary Indications in Patients with CancerTo protect bone from new metastatic lesionsTo treat hypercalcemia of malignancyTo prevent treatment-related bone demineralization, osteolysis, and pathologic fracturesTo treat osteolytic lesions, decrease the incidence of pathologic fractures, prevent skeletal deformities, and prevent and decrease the severity of pain SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/07 UR - hemonc.mhmedical.com/content.aspx?aid=1128367588 ER -